CHAIRMAN OF AMGEN FILES TO SELL 100,000 SHARES.Byline: Stuart D. Luman Bloomberg News Amgen Inc. Chairman Gordon M. Binder filed to sell 100,000 shares, almost 7 percent of the 1.5 million shares he owns, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. regulatory filings. Binder, chief executive officer of the world's largest biotechnology company, filed Friday to sell the shares. They would be worth $6.2 million based on Monday's closing price. Amgen fell 1-1/2 to 62 1/16. Binder and company officials weren't immediately available for comment. He last sold Amgen stock in May, when he sold 84,000 shares. The company's share price rose to a one-year high of 65 9/16 in late May on takeover speculation. Business Week magazine has reported that Delaware-based Dupont Co. would make a $25 billion cash offer for the company. Both companies have declined to comment. The company sells two blockbuster drugs whose annual sales exceed $1 billion - Epogen, for anemic anemic pertaining to anemia. dialysis patients, and Neupogen, which is used to treat a weakened immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Amgen's genetically engineered genetically engineered adjective Recombinant, see there version of leptin Leptin A protein hormone that affects feeding behavior and hunger in humans. At present it is thought that obesity in humans may result in part from insensitivity to leptin. , a hormone linked to obesity, was found safe and effective for weight loss in very early clinical trials, researchers said last week. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion